Author Archives: Janet Stewart, MSc

Rituxan Successfully Treated Severe Neuropsychiatric Lupus, Case Report Says

A 49-year-old woman with severe demyelinating syndrome systemic lupus erythematosus (DS-SLE), where lupus affects the white matter in the brain, was successfully treated with Genentech‘s Rituxan (rituximab), along with other medications. The case report, “Severe neuropsychiatric systemic lupus erythematosus successfully treated with rituximab: an alternative to…

Anthera’s Blisibimod Granted Orphan Drug Status for Inflammatory Kidney Disease

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to the investigative therapy blisibimod for the treatment of immunoglobulin A nephropathy (IgAN), according to Anthera Pharmaceuticals, the drug’s developer. IgAN, or Berger’s disease, is the main cause of primary glomerulonephritis — inflammation of the kidneys — associated with…

Scientists Studying Mice Isolate T-bet Protein, a Possible Trigger for Lupus, Other Autoimmune Diseases

Researchers at Denver’s National Jewish Health have prevented autoimmune disease in mice prone to a lupus-like illness by eliminating a protein called T-bet. This protein, which helps transform a type of white blood cell into an age-associated B-cell (ABC), may be a possible therapeutic target for treating lupus, multiple sclerosis, Crohn’s disease…

People at High Risk for Lupus Can Be Identified Through Blood Test

Researchers have devised a blood test that predicts which blood relatives of patients with systemic lupus erythematosus (SLE) — people who are at high risk of developing the disease — will actually develop it, even seven years before the disease declares itself. The blood test can be used to provide preventive…